Panacea Biotec has bagged orders worth Rs 170 crore (US$ 24.32 million) from UN agencies, including UNICEF, for the supply of Pentavalent vaccine.
The vaccine has a role in providing protection against five deadly diseases, including diphtheria, tetanus and hepatitis B to children.
“Panacea Biotec… has received awards worth US$ 24.32 million from U N agencies (UNICEF and PAHO) for supply of its Easy five-TT, a fully liquid WHO prequalified wP-based Pentavalent vaccine (DTwPHepB-Hib),” according to the company filing to BSE.
This award of order from UNICEF is for the calendar year 2020 and for three calendar years that include 2020 to 2022 from PAHO.
These pediatric vaccination have a major role in particular to reach the target set by United Nation under Sustainable Development Goals. The goal is to reduce under-five mortality rate to less than 25 per 1,000 live births.
“Pentavalent vaccine protects children against five deadly diseases; Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b – becoming the foundation of paediatric immunisation programs across the world,” the company said.
Source: IBEF
Image Course: NewsBeezer
You may also like
-
India’s AI Opportunity Lies in Applications, Data Centres and Green Energy, Says Ashwini Vaishnaw
-
Indian Railways to Build 238 AC EMU Rakes for Mumbai Suburban Network, Deliveries to Begin in 2027
-
India and Singapore Push Strategic Partnership into Semiconductors, AI, Fintech and Advanced Manufacturing
-
Raphe mPhibr — Building India’s Vertically Integrated Military Drone Ecosystem
-
Armenia Reportedly Moves Closer to Pralay Missile Deal as Defence Ties With India Deepen
